News

Article

HD-CAR-1 Treatment Is Safe and Feasible in Heavily Pretreated CLL

Author(s):

Fact checked by:

Key Takeaways

  • HD-CAR-1 therapy achieved a 67% complete remission rate in heavily pretreated CLL patients, with 83% showing undetectable minimal residual disease.
  • CD4-positive T cells were more prevalent in responders, while nonresponders had effector memory-like CD8-positive T cells with high CD39/CD197 expression.
SHOW MORE

Treatment with the third-generation anti-CD19 CAR T-cell therapy HD-CAR-1 is feasible and safe in heavily pretreated chronic lymphocytic leukemia.

HD-CAR-1 in Heavily Pretreated CLL | Image Credit: © Dr_Microbe - stock.adobe.com

HD-CAR-1 in Heavily Pretreated CLL |

Image Credit: © Dr_Microbe - stock.adobe.com

Treatment with the third-generation anti-CD19 CAR T-cell therapy HD-CAR-1 is feasible and associated with a tolerable toxicity profile in patients with heavily pretreated chronic lymphocytic leukemia (CLL), according to data from a phase 1/2 trial (NCT03676504) published in Leukemia.

In this investigation, 9 patients were treated with HD-CAR-1 at dose levels ranging from 1 × 106 to 200 × 106 CAR T cells/m2; in-house manufacturing of HD-CAR-1 was successful for all patients. In total, by day 90, 67% of patients had a complete remission (CR), 83% of whom had undetectable minimal residual disease (MRD). Moreover, at a median follow-up of 27 months, the 2-year progression-free and overall survival rates were 30% and 69%, respectively.

Investigators also noted that HD-CAR-1 products derived from responders contained significantly more CD4-positive T cells compared with those from nonresponders, and that in nonresponders, a strong enrichment of effector memory-like CD8-positive T cells with high expression of CD39 and/or CD197 was observed.

“Treatment of heavily pretreated patients with high-risk CLL having [progressed on] multiple pathway inhibitors with the third-generation CAR T HD-CAR-1 is feasible and associated with only very modest CAR T–specific toxicity. The preliminary efficacy signals obtained suggest that HD-CAR-1 can induce prolonged CRs in otherwise refractory patients and warrant further exploration of this approach,” study authors wrote in a report of the data.

Although the utility of second-generation CD19-directed CAR T-cell therapy has shifted the treatment paradigm for patients with B-cell malignancies, patients with CLL still do not achieve superior response rates or longer durations of response compared with patients with other indolent B-cell lymphomas. Due to a dearth of data [in this area], investigators sought to further investigate findings with third-generation CAR T-cell therapies manufactured academically.

In this basket trial of patients with relapsed/refractory CLL, investigators aimed to assess the feasibility of and identify dose-limiting toxicities of HD-CAR-1 CAR T-cell therapy. Eligible patients included those with CLL who had progressed on 2 or more lines of therapy, including at least 1 pathway inhibitor or allogeneic hematopoietic cell transplantation (alloHCT), and had an ECOG performance score of 0 or 1.

Patients received treatment with HD-CAR-1 at increasing doses of autologous T cells retrovirally transduced with a third-generation CD19-directed CAR in a 3 + 3 design; CARs were manufactured at the institutional Good Manufacturing Practice Core Facility. HD-CAR-1 CAR T-cell therapy was given 2 days following administration of lymphodepletion with fludarabine at 30 mg/m2 per day and cyclophosphamide at 500 mg/m2 per day for 3 days.

Adverse effects, such as cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and immune effector cel­-associated hematotoxicity (ICAHT), were graded according to consensus guidelines and managed according to institutional guidelines. Additionally, during lymphodepletion, CAR T-cell infusion, and monitoring, patients were hospitalized from day −6 through day +14.

In total, 8 patients with relapsed/refractory CLL were enrolled onto the investigator-led trial between October 2018 and May 2023; a ninth patient was treated compliant with the trial but formally off-study in July 2023 after having given fully informed consent.

The median age of patients enrolled was 60 years (range, 45-68). Patients had received a median of 5 (range, 2-10) prior treatment lines, 44% of patients had received prior alloHCT, and 78% of patients harbored TP53 abnormalities. One hundred percent of patients had progressed on Bruton’s tyrosine kinase inhibitors and had received at least 1 venetoclax (Venclexta)–based regimen; 8 patients were refractory to venetoclax-based treatment as well. Moreover, bridging therapy was administered to 100% of patients, mostly with venetoclax-antibody combinations, resulting in CR and partial remission in 3 and 2 patients, respectively. All patients had flow-detectable MRD at lymphodepletion. One patient also had a history of Richter transformation, which was not present at the time of enrollment.

Manufacturing results of HD-CAR-1 were successful in all 9 patients, with a median transduction efficiency of 52.3% (range, 41.7%-67.7%) and a median CAR T viability of 95.2% (range, 86.2%-95.8%). The median duration of manufacturing was 13 days (range, 10-13); in 2 patients, a second leukapheresis had to be performed due to an unfavorable T-cell:B-cell ratio in the first leukapheresis products.

Furthermore, 100% of patients received at least 1 dose of HD-CAR-1 CAR T cells. “Dose levels were DL1 [1 × 106 CAR T cells/m2] in 1 patient, DL2 [5 × 106 CAR T cells/m2] in [1 patient], DL5 [10 × 107 CAR T cells/m2] in 2 patients, and DL6 [20 × 107 CAR T cells/m2] in 5 patients,” the study authors shared.

Overall, HD-CAR-1 CAR T-cell therapy was well tolerated. Regarding safety, higher-grade CRS was observed in 11% of patients, and no ICANS was observed. Early ICAHT occurred in 89% of patients and was grade 4 in 11% of patients. Late ICAHT was observed at grades 1 and 2 in 1 and 2 patients, respectively, without the need for granulocyte colony-stimulating factor support. Hypogammaglobulinemia was observed in 8 patients at lymphodepletion, 1 of which showed recovery of gamma globulin levels following HD-CAR-1 treatment. One patient did not exhibit hypogammaglobulinemia at lymphodepletion or after day 90 post-CAR T infusion. Intravenous immunoglobulins were administered to 3 patients following treatment.

Furthermore, early infections post-CAR T-cell infusion occurred in 1 patient who presented with herpes simplex virus type 1 infection of the lower lip and respiratory infection without pathogen identification. Late infections, classified as those occurring beyond day 30, occurred in 4 patients.

Rapid CAR T expansion in the peripheral blood was observed in 89% of patients with a median CAR T peak level of 82,358 CAR T/µg peripheral blood mononuclear cell (PBMC) DNA (range 37,792-369,756). The study authors noted that, “In all 7 patients evaluated, CAR T cells were persistent at end of study. Five patients were evaluated beyond 100 days after HD-CAR-1 infusion, with detectable CAR T cells in the peripheral blood of all patients. [One] patient still showed 202 CAR T/µg PBMC DNA even at day 994 after HD-CAR-1 infusion, and in [another patient], a particularly high CAR T concentration was observed with 18,199 and 13,521 CAR T/µg PBMC DNA at days 171 and 295, respectively.”

All the patients with a CR as best response presented with B-cell aplasia at end of study on day 90 after CAR T-cell therapy administration; 2 patients showed absolute T-cell counts above the lower limit of normal but presented with counts below the lower limit of normal at day 200 after CAR T-cell therapy administration. B-cell and T-cell recovery took place on day 450 along with ongoing CR with undetectable MRD in 1 patient. B-cell aplasia and lymphopenia were still present in 4 patients at their latest assessment on days 771, 548, 198, and 301, respectively, after CAR T-cell therapy administration.

“This confirms the results of HD-CAR-1 in patients, where a low CD39-expression on effector T cells within the CAR T product was associated with a higher response rate. This clinical confirmation strengthens the role of CD39 within CAR T products as a marker for T-cell exhaustion and possible predictor of response in CAR T,” the authors concluded.

Reference

Derigs P, Schubert ML, Dreger P, et al. Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study. Leukemia. 2024;38:2419–2428. doi:10.1038/s41375-024-02392-7

Related Videos
John M. Burke, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
David C. Fisher, MD
David C. Fisher, MD
Nitin Jain, MD
Kathleen A. Dorritie, MD
Alexey Danilov, MD, PhD